Overview

US General Anesthesia Drugs Market is poised to value over USD 2.5 billion by 2027 end at a CAGR of over 3.2% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of US General Anesthesia Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the US General Anesthesia Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the US General Anesthesia Drugs Market:
• Baxter International Inc.
• Hikma Pharmaceuticals plc
• Pfizer Inc.
• Piramal Enterprises Limited AbbVie
• Fresenius SE & Co. KGaA
• Par Pharmaceutical
• Teva Pharmaceuticals
• Viatris/Mylan
• Novartis AG
• Abbott Laboratories
• AstraZeneca plc
• F.Hoffmann-La Roche
• GlaxoSmithKline plc
• Gilead Sciences, Inc.
• Bayer AG
• Merck & Co., Inc.
• Sanofi
• Heritage Pharmaceuticals Inc
• Akorn
• Apotex
(Note: The list of the major players will be updated with the latest market scenario and trends)

US General Anesthesia Drugs Market Segmentation:
By Route of Administration
• Inhalational
 o Sevoflurane
 o Desflurane
 o Isoflurane
 o Nitrous Oxide
• Intravenous
 o Propofol
 o Benzodiazepines
 o Ketamine
 o Methohexital Sodium
 o Others

By End User  
• Hospitals
• Ambulatory Surgery Centers

By Company Type
• Tier 1 Pharmaceutical Companies
• Tier 2 Pharmaceutical Companies
• Tier 3 Pharmaceutical Companies

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the US General Anesthesia Drugs Market By Route of Administration, By End User, By Company Type and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— US
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4.  US General Anesthesia Drugs Market Variables, Trends & Scope
  4.1. Market LineProducts Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of US General Anesthesia Drugs Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6.  US General Anesthesia Drugs Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. US General Anesthesia Drugs Market, By Route of Administration Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Inhalational
       7.1.1. Sevoflurane
       7.1.2. Desflurane
       7.1.3. Isoflurane
       7.1.4. Nitrous Oxide
  7.2. Intravenous
       7.2.1. Propofol
       7.2.2. Benzodiazepines
       7.2.3. Ketamine
       7.2.4. Methohexital Sodium
       7.2.5. Others

8. US General Anesthesia Drugs Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)  
  8.1. Hospitals
  8.2. Ambulatory Surgery Centers

9. US General Anesthesia Drugs Market, By Company Type Historical Analysis and Forecast 2020-2027 (USD Million)  
  9.1. Tier 1 Pharmaceutical Companies
  9.2. Tier 2 Pharmaceutical Companies
  9.3. Tier 3 Pharmaceutical Companies

10. Market Share Analysis and Competitive Landscape  
   10.1.  U.S Landscape - Key Players, Revenue and Presence
   10.2.  U.S Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   10.3.  U.S Emerging Companies
   10.4.  U.S - Market Share Analysis and Key Regional Players
   10.5.  U.S Key Player - Growth Matrix

11. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   11.1. Baxter International Inc.
         11.1.1. Company Overview
         11.1.2. Product Portfolio
         11.1.3. SWOT Analysis
         11.1.4. Financial Overview
         11.1.5. Strategic Overview
   11.2. Hikma Pharmaceuticals plc
         11.2.1. Company Overview
         11.2.2. Product Portfolio
         11.2.3. SWOT Analysis
         11.2.4. Financial Overview
         11.2.5. Strategic Overview
   11.3. Pfizer Inc.
         11.3.1. Company Overview
         11.3.2. Product Portfolio
         11.3.3. SWOT Analysis
         11.3.4. Financial Overview
         11.3.5. Strategic Overview
   11.4. Piramal Enterprises Limited
         11.4.1. Company Overview
         11.4.2. Product Portfolio
         11.4.3. SWOT Analysis
         11.4.4. Financial Overview
         11.4.5. Strategic Overview
   11.5. Fresenius SE & Co. KGaA
         11.5.1. Company Overview
         11.5.2. Product Portfolio
         11.5.3. SWOT Analysis
         11.5.4. Financial Overview
         11.5.5. Strategic Overview          
   11.6. Par Pharmaceutical
         11.6.1. Company Overview
         11.6.2. Product Portfolio
         11.6.3. SWOT Analysis
         11.6.4. Financial Overview
         11.6.5. Strategic Overview      
   11.7. Teva Pharmaceuticals
         11.7.1. Company Overview
         11.7.2. Product Portfolio
         11.7.3. SWOT Analysis
         11.7.4. Financial Overview
         11.7.5. Strategic Overview
   11.8. Viatris/Mylan
         11.8.1. Company Overview
         11.8.2. Product Portfolio
         11.8.3. SWOT Analysis
         11.8.4. Financial Overview
         11.8.5. Strategic Overview
   11.9. Novartis AG
         11.9.1. Company Overview
         11.9.2. Product Portfolio
         11.9.3. SWOT Analysis
         11.9.4. Financial Overview
         11.9.5. Strategic Overview
   11.10.Abbott Laboratories
         11.10.1. Company Overview
         11.10.2. Product Portfolio
         11.10.3. SWOT Analysis
         11.10.4. Financial Overview
         11.10.5. Strategic Overview
   11.11.AstraZeneca plc
         11.11.1. Company Overview
         11.11.2. Product Portfolio
         11.11.3. SWOT Analysis
         11.11.4. Financial Overview
         11.11.5. Strategic Overview
   11.12.F.Hoffmann-La Roche
         11.12.1. Company Overview
         11.12.2. Product Portfolio
         11.12.3. SWOT Analysis
         11.12.4. Financial Overview
         11.12.5. Strategic Overview
   11.13.GlaxoSmithKline plc
         11.13.1. Company Overview
         11.13.2. Product Portfolio
         11.13.3. SWOT Analysis
         11.13.4. Financial Overview
         11.13.5. Strategic Overview
   11.14.Gilead Sciences, Inc.
         11.14.1. Company Overview
         11.14.2. Product Portfolio
         11.14.3. SWOT Analysis
         11.14.4. Financial Overview
         11.14.5. Strategic Overview
   11.15.Bayer AG
         11.15.1. Company Overview
         11.15.2. Product Portfolio
         11.15.3. SWOT Analysis
         11.15.4. Financial Overview
         11.15.5. Strategic Overview
    11.16.Merck & Co., Inc.
         11.16.1. Company Overview
         11.16.2. Product Portfolio
         11.16.3. SWOT Analysis
         11.16.4. Financial Overview
         11.16.5. Strategic Overview
   11.17.Sanofi
         11.17.1. Company Overview
         11.17.2. Product Portfolio
         11.17.3. SWOT Analysis
         11.17.4. Financial Overview
         11.17.5. Strategic Overview
   11.18.Heritage Pharmaceuticals Inc
         11.18.1. Company Overview
         11.18.2. Product Portfolio
         11.18.3. SWOT Analysis
         11.18.4. Financial Overview
         11.18.5. Strategic Overview
   11.19.Akorn
         11.19.1. Company Overview
         11.19.2. Product Portfolio
         11.19.3. SWOT Analysis
         11.19.4. Financial Overview
         11.19.5. Strategic Overview
   11.20.Apotex
         11.20.1. Company Overview
         11.20.2. Product Portfolio
         11.20.3. SWOT Analysis
         11.20.4. Financial Overview
         11.20.5. Strategic Overview
   
13. Pre and Post COVID-19 Impact
   13.1. Positive influence on the healthcare industry
   13.2. The financial disruption of the manufacturing sector
   13.3. Impact of COVID-19 on emerging companies
   13.4. Significant mandates in the healthcare regulations initiated by administrations
   13.5. The overall economic slowdown of the developing and developed nations

14. FutureWise SME Key Takeaway Points for Client

Tables

Figures